Cardiac Translational Assays Tony Rush
High quality cardiac toxicity data generation and interpretation is vital to the efficient progression of a drug discovery campaign. Metrion offers a range of translational, phenotypic cardiac assays and platforms that have been validated using a number of commercially available iPSC-derived cardiomyocyte cell lines. Using technologies such as manual patch clamp electrophysiology, microelectrode array (MEA; Maestro platform) or dual MEA/impedance readouts (CardioExcyte96), Metrion can offer a direct readout of physiological function in the iPSC-derived cardiomyocyte cell line of your choosing.
Metrion has considerable expertise working with iPSC-derived cardiomyocytes on the manual patch clamp platform. The company has access to, and has characterised, a wide range of commercially available cell lines on behalf of a number of vendors. Metrion offers services to screen compounds against action potentials and membrane currents recorded from iPSC-derived cardio myocytes. Furthermore, we provide a cell line characterisation service for companies and vendors looking to commercialise their cell lines.
Metrion has developed plate-based iPSC-derived cardiomyocyte assays using MEA and impedance platforms to add further depth to our range of CiPA-compliant assays. Metrion has access to, and has characterised, a wide range of commercially available iPSC-derived cardiomyocyte cell lines on behalf of a number of vendors. Phenotypic readouts can be correlated with modelling predictions and electrophysiology readouts as part of an integrated CiPA approach.